Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
DRUG CLASS:
ICOS agonist
DRUG CLASS:
ICOS agonist
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Related drugs:
‹
GSK3359609 (2)
JTX-2011 (1)
BMS-986226 (0)
ICOSL vIgD (0)
SAR445256 (0)
GSK3359609 (2)
JTX-2011 (1)
BMS-986226 (0)
ICOSL vIgD (0)
SAR445256 (0)
›
Associations
(3)
News
Trials
Phase
Status
Apply
Phase
Status
Apply
Dose Escalation and Expansion Study of GSK3359609 in Participants With Selected Advanced Solid Tumors (INDUCE-1) (NCT02723955)
Phase 1
GlaxoSmithKline
GlaxoSmithKline
Completed
Phase 1
GlaxoSmithKline
Completed
Last update posted :
12/27/2024
Initiation :
06/23/2016
Primary completion :
07/05/2023
Completion :
07/05/2023
MSI • ICOS
|
MSI-H/dMMR
|
Keytruda (pembrolizumab) • cisplatin • carboplatin • gemcitabine • paclitaxel • docetaxel • 5-fluorouracil • pemetrexed • Jemperli (dostarlimab-gxly) • bintrafusp alfa (M7824) • cobolimab (TSR-022) • feladilimab (GSK3359609) • GSK3174998
Platform Trial of Novel Regimens Versus Standard of Care (SoC) in Participants With Non-small Cell Lung Cancer (NSCLC) - Sub-study 1 (NCT05553808)
Phase 2
GlaxoSmithKline
GlaxoSmithKline
Completed
Phase 2
GlaxoSmithKline
Completed
Last update posted :
01/19/2023
Initiation :
01/24/2019
Primary completion :
09/23/2021
Completion :
09/23/2021
BRAF
|
docetaxel • feladilimab (GSK3359609)
Share
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login